ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

Contract Authority Expiration Confuses NCI Money Bill Estimates, Which Range From $605 To $650 Million

June 21, 1974

New ACS Structure Proposed, approved

August 6, 1993

Texas Oncology Designated Aranesp As Preferred Treatment

December 13, 2002

NCI Launches M-PACT Next-Generation Trial As Group System Nears March 1 Transition

February 21, 2014

AACR Unanimously Backs Tough Antismoking Measure

May 18, 1984

SWOG Five Drug Adjuvant Breast Study Shows Remarkable Survival For Older, Younger Women

March 30, 1979